Glivec

• Novartis on patent setback: Will continue to invest in India, but cautiously

  Novartis India Limited, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.

• Supreme Court's decision on Novartis AG to benefit poor patients, say pharma companies

  Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic manufacturers.

• Supreme Court backs generics in Novartis drug patent ruling

  India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic drugs and save lives in developing nations.

• Supreme Court rejects Novartis AG's plea for cancer drug patent: Read full verdict

  The Supreme Court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales. Here is the copy of the full verdict:

• Novartis AG's plea for Glivec patent dismissed by Supreme Court

  The Supreme Court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.

• Pharma giant Novartis waits nervously on Glivec drug patent verdict

  Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country.

• Supreme Court's verdict on Novartis' plea for patent of cancer drug expected today

  The Supreme Court will pronounce today its verdict on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India and restraining Indian companies from manufacturing generic drugs.

• Indian patients go to court over drug

  Cancer Patients Aid Association has challenged the government's decision to grant Novartis the exclusive marketing rights for imatinib, a drug that has emerged as a frontline treatment for chronic myeloid leukaemia.